A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Dostarlimab (Primary) ; TSR 033 (Primary)
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms CITRINO
- Sponsors TESARO
- 23 Oct 2019 Planned number of patients changed from 260 to 200.
- 09 Nov 2018 According to a TESARO media release, preliminary results (n=30) of the monotherapy dose-escalation portion from this study, were presented at the 2018 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Conference in Washington, D.C.
- 09 Nov 2018 Preliminary results (n=30) of the monotherapy dose-escalation portion from this study presented in a TESARO media release.